Error loading player: No playable sources found

AM23-MN-10-O

AM23-MN-10-O: Weak RhD Phenotypes and RHD Genotyping: Who, What, When, Where, How? (Enduring)

Credits
1 General Continuing Education (GEN) | 1 Florida Lab Personnel (FLP) | 1 California Nurse (CN) | 1 California Lab Personnel (CLP) | 1 Physician (PHY)
$3000
Standard Price
Members save $5

It’s been eight years since the AABB-CAP-ACOG working party first recommended RHD genotyping for patients with weak D phenotypes; how are we doing, and what are we finding? This session will discuss the identification of weak D phenotypes in manual and automated patient test methods and synthesize lessons learned from genotyping weak D phenotypes found among over a million patients in the US and Canada in published series. We will describe the current American status of RHD genotyping services, how serological and molecular methods influence the RHD genotyping findings, what are the most frequent partial RHD variants seen in these patients, and what is known about their risk for allo-anti-D. If you and your care providers have questions about weak D phenotypes, when to obtain genotyping, and what the genotypes mean, we’ll provide answers in an efficient interactive format geared to practical application.

Learning Objectives

  • Identify manual and automated weak D serological criteria for obtaining RHD genotyping
  • Discuss the influences of serological methods, genotyping techniques and patient race/ethnicities on RHD genotyping results
  • Describe which weak partial RHD variants are at most risk for anti-D formation
  • Review how to apply RHD genotyping results to Rh Immune Globulin therapy and RhD-negative transfusions

Moderator

Speaker Image for Glenn Ramsey
Professor of Pathology, Feinberg School of Medicine, Northwestern University

Speaker

Speaker Image for Sandra Nance
Sandra J. Nance, MS, MASCP, MT(ASCP)SBB
Adjunct Assistant Professor, University of Pennsylvania

Tracks

Related Products

Thumbnail for AM24-ST-18-O: AABB RBC and Platelet International Guidelines: What is New: Liberally Restrictive and Restrictively Liberal? (Enduring)
AM24-ST-18-O: AABB RBC and Platelet International Guidelines: What is New: Liberally Restrictive and Restrictively Liberal? (Enduring)
The AABB continues to update and develop clinical transfusion guidelines as new evidence becomes available…
Thumbnail for AM24-ST-29-O: Case Studies: Cyber Threats in Healthcare (Enduring)
AM24-ST-29-O: Case Studies: Cyber Threats in Healthcare (Enduring)
Join us for an essential panel discussion on cybersecurity in healthcare, where real-world insights and expert analysis come together to enhance your organization's defenses. This session features three distinguished speakers from hospitals and blood centers that have faced cybersecurity attacks…
Thumbnail for AM24-MN-36-O: From Courts to Congress: Navigating the Healthcare Policy Landscape in 2024 (Enduring)
AM24-MN-36-O: From Courts to Congress: Navigating the Healthcare Policy Landscape in 2024 (Enduring)
In today’s rapidly evolving healthcare environment, understanding the latest policy developments is crucial for strategic planning and operational success. This session will explore the significant implications of the recent Supreme Court decision – Loper Bright Enterprises v…
Thumbnail for AM24-MN-43-O: Trans, Non-binary, and Gender-Diverse Peoples: How You Can Make a Difference for Donors, Patients, and Communities (Enduring)
AM24-MN-43-O: Trans, Non-binary, and Gender-Diverse Peoples: How You Can Make a Difference for Donors, Patients, and Communities (Enduring)
Many blood operators around the world are implementing individualized donor assessments that welcome more trans, non-binary, and gender-diverse people to donate…